Related Experiment Video

Updated: May 4, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

17.4K

Treating paediatric community-acquired pneumonia in the era of antimicrobial resistance

L Galli1, C Montagnani, E Chiappini

  • 1Department of Health Sciences, University of Florence, Anna Meyer Children's University-Hospital, Florence, Italy.

Acta Paediatrica (Oslo, Norway : 1992)
|December 17, 2013
PubMed

Insights

Community-acquired pneumonia (CAP) in children is rising due to drug-resistant bacteria. Pediatricians must use local resistance data for effective treatment and judicious antimicrobial use.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Paediatric community-acquired pneumonia (CAP) is increasing globally.
  • Drug-resistant bacteria and antimicrobial resistance are significant challenges in CAP treatment.
  • Prevalence of CAP varies by age, country, and specific bacterial serotypes.

Purpose of the Study:

  • To highlight the challenges posed by antimicrobial resistance in paediatric CAP.
  • To emphasize the need for evidence-based treatment strategies.
  • To advocate for judicious antimicrobial use.

Main Methods:

  • This study is a review of current literature and epidemiological data on paediatric CAP.
  • Analysis of resistance patterns and treatment outcomes.
  • Focus on the impact of antimicrobial resistance on clinical practice.

Main Results:

  • Increasing incidence of CAP caused by drug-resistant pathogens.
  • Variability in resistance patterns across different regions and age groups.
  • First-line empirical treatments often fail due to resistance.

Conclusions:

  • Local epidemiological data on resistance is crucial for effective CAP management.
  • Paediatricians must consider second-line treatments based on local resistance prevalence.
  • Judicious use of antimicrobial agents is essential to combat antimicrobial resistance.
Abstract

Keywords:
Antimicrobial resistanceChildrenCommunity-acquired pneumoniaDrug-resistant bacteriaPaediatricians

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.3K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.2K
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
219
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
84
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
24
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.5K